Barclays’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-133,703
| Closed | -$4.61M | – | 5294 |
|
|
2020
Q3 | $4.61M | Buy |
133,703
+55,721
| +71% | +$1.19M | ﹤0.01% | 1449 |
|
|
2020
Q2 | $1.3M | Sell |
77,982
-9,681
| -11% | -$164K | ﹤0.01% | 2518 |
|
|
2020
Q1 | $1.26M | Buy |
87,663
+5,539
| +7% | +$142K | ﹤0.01% | 2720 |
|
|
2019
Q4 | $2.75M | Buy |
82,124
+24,198
| +42% | +$676K | ﹤0.01% | 2665 |
|
|
2019
Q3 | $1.21M | Buy |
57,926
+19,026
| +49% | +$388K | ﹤0.01% | 3476 |
|
|
2019
Q2 | $810K | Buy |
38,900
+24,153
| +164% | +$497K | ﹤0.01% | 3903 |
|
|
2019
Q1 | $330K | Buy |
14,747
+12,372
| +521% | +$291K | ﹤0.01% | 4448 |
|
|
2018
Q4 | $57K | Sell |
2,375
-62,153
| -96% | -$1.61M | ﹤0.01% | 5409 |
|
|
2018
Q3 | $1.76M | Buy |
64,528
+58,982
| +1,064% | +$1.67M | ﹤0.01% | 3035 |
|
|
2018
Q2 | $150K | Sell |
5,546
-18,779
| -77% | -$575K | ﹤0.01% | 4973 |
|
|
2018
Q1 | $775K | Sell |
24,325
-131,803
| -84% | -$4.64M | ﹤0.01% | 3515 |
|
|
2017
Q4 | $5.91M | Buy |
156,128
+100,665
| +181% | +$3.25M | ﹤0.01% | 1536 |
|
|
2017
Q3 | $1.37M | Buy |
55,463
+55,359
| +53,230% | +$1.19M | ﹤0.01% | 2703 |
|
|
2017
Q2 | $3K | Sell |
104
-4,993
| -98% | -$95.3K | ﹤0.01% | 6379 |
|
|
2017
Q1 | $111K | Buy |
5,097
+835
| +20% | +$17.1K | ﹤0.01% | 4808 |
|
|
2016
Q4 | $86K | Buy |
4,262
+3,839
| +908% | +$78.5K | ﹤0.01% | 4858 |
|
|
2016
Q3 | $6K | Buy |
+423
| New | +$5.71K | ﹤0.01% | 5969 |
|
Barclays's AIMT Position: Q4 2020 in Review
Barclays sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 133,703 shares — an estimated $4.61M sold.
Barclays first reported a position in AIMT in Q3 2016 and held it in 17 quarters. The position peaked at $5.91M in Q4 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Barclays reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Barclays sold 133,703 Aimmune Therapeutics shares in Q4 2020, an estimated $4.61M.
- Barclays first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 17 quarters.
- Barclays's Aimmune Therapeutics position peaked at $5.91M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.